Lilly(Eli) & Co
LLY
Market Cap$796.27B
Close$
Earnings Call Q4 2024
February 6, 2025 - AI Summary
Revenue Growth: Eli Lilly reported a 32% increase in full-year revenue for 2024 compared to 2023, exceeding guidance by $4 billion. Q4 2024 revenue grew 45%, driven by strong sales of newly launched products, including a $3.5 billion contribution from Mounjaro and $1.9 billion from Zepbound.
Strong Pipeline Advancements: Lilly remains committed to expanding its pipeline, initiating new Phase III programs and acquiring external assets. In 2024, they started 8 new Phase III programs and received approvals for Kisunla, Ebglyss, Zepbound (new indication for OSA), and Omvoh (for Crohn’s disease). The company expects to continue strengthening its portfolio through additional regulatory submissions in 2025.
2025 Guidance: For 2025, Lilly forecasts revenue of $58 billion to $61 billion, indicating a growth rate of approximately 32% from 2024. This guidance is built on the assumption of continued prescription growth for incretin products and new market launches, alongside expectations for ongoing growth in oncology, neuroscience, and immunology.
Exclusive for Stockcircle Pro members
Sign up
$376.39
54.5% downside
Current Fair Value
54.5% downsideOvervalued by 54.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $796.27 Billion |
|---|---|
| Enterprise Value | $796.27 Billion |
| Dividend Yield | $6 (0.642887756559836%) |
| Earnings per Share | $11.8 |
| Beta | 0.5 |
| Outstanding Shares | 903,647,540 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 71.67 |
|---|---|
| PEG | -4 |
| Price to Sales | 18.39 |
| Price to Book Ratio | 55.17 |
| Enterprise Value to Revenue | 19.49 |
| Enterprise Value to EBIT | 65.13 |
| Enterprise Value to Net Income | 95 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Lilly(Eli) & Co
CEO: David Ricks